Clinical Trial Update: A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating REGN5668 with cemiplimab, cemiplimab plus fianlimab, or ubamatamab in adult women with ovarian cancer, fallopian tube canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Fianlimab (fianlimab)
• REGN5668
• Ubamatamab (ubamatamab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: RECRUITING